Terns Pharmaceuticals, Inc.
TERN
Rang in aandelen
#3581
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Aandeelprijs
$52.95
Laatst gesynchroniseerd: 2026-05-15
Marktkapitalisatie
$4.77B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
552.09%
Land
US
Handel Terns Pharmaceuticals, Inc. (TERN)
Categorie
Healthcare
Koersgeschiedenis voor Terns Pharmaceuticals, Inc. (TERN)
Hoogste slotkoers: $52.95 op 2026-05-01
Laagste slotkoers: $20.53 op 2021-02-01
Laagste slotkoers: $20.53 op 2021-02-01
Koersgeschiedenis van Terns Pharmaceuticals, Inc. van 2021 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | -1.17% |
| 2025 | 517.55% |
| 2024 | -2.74% |
| 2023 | -12.48% |
| 2022 | 13.79% |
| 2021 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
